retatrutide phase 2 obesity trial results Early data for demonstrates exceptional weight loss results, reaching approximately 21% placebo-adjusted weight loss by week 48. This performance significantly exceeds all other leading medications currently under Phase 2 Trial of Retatrutide

13 Drug surveys have shown that most patients remain at the starting dose

Zepbound is FDA-approved as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

15,392 In Wistar rats, a diet high in fat was found to lead to a decrease in the ratio of OPG/RANKL, which resulted in increased bone resorption and ultimately a reduction in bone mass

GLP-1 is also an incretin hormone, enhancing insulin and suppressing glucagon secretion in the pancreas, thus lowering blood glucose

But as interest in semaglutide for weight loss continues to grow, health care professionals are finding ways to manage the demand